Organization & Developments: BridgeBio Pharma

Parents

BridgeBio Pharma Inc. (NASDAQL BBIO)*

Children

' BridgeBio acquires rights to these compounds and builds companies around them.
*BridgeBio focuses on developing drugs for rare diseases that stem from defects in a single gene, as well as cancers that have clear genetic drivers.
*The company’s model involves finding overlooked research at universities or on the shelves of pharmaceutical companies.
2020: Calcilytix Initiates Phase 2 Study Of Encaleret for ADH1
2021: BridgeBio spins gold out of an Alexion castoff, scoring an FDA approval in rare metabolism disorder
2021: Neil Kumar's BridgeBio finds 7 new academic partners to join the fight against genetic disease
2022: BridgeBio strategy head departs amid company's 2nd round of layoffs this year
2023: BridgeBio Pharma: Taking Some Profits_ seekingalpha.com
2023: BridgeBio: Bets Acoramidis As The Pfizer Spoiler
2023: Positive Updated Acoramidis Data May Not Imply Further Upside (NASDAQ:BBIO)
2024: BridgeBio Grows Up, Trims Pipeline as It Leans Into Late-Stage Assets
2024: BridgeBio heart drug approved by FDA, setting up battle with Pfizer
2024: BridgeBio Pharma: Assessing Acoramidis' Market Opportunity, Further Upside Potential Evident
2024: BridgeBio Pharma: FDA Submission Acromidis And Top Line Results On Deck_ seekingalpha.com
2024: BridgeBio Pharma: Upping An Existing Position (Rating Upgrade)_seekingalpha
2024: BridgeBio Pharma's Acoramidis Leads Promising Pipeline With FDA Approval On Horizon_ seekingalpha
2024: BridgeBio Pharma's Robust Pipeline Could Benefit From A Partner_ seekingalpha.com
2024: BridgeBio slashes gene therapy budget after early-phase data fall short of 'transformational' target
2024: BridgeBio: 2 Weeks Until Major Drug Approval Catalyst - A Buy, With Caveats_seekingalpha.com
2024: BridgeBio: PDUFA Date Expected In November 2024 Could Shift Momentum
2024: BridgeBio's Acoramidis Nears FDA Approval; $500M Milestone Payment Awaits
2024: BridgeBio's Attruby Wins FDA Approval: 42% Reduction in ATTR-CM Mortality & Hospitalizations
2025: BridgeBio drug for rare form of muscular dystrophy posts positive data in key trial
2025: BridgeBio Pharma Is A Buy On Dips After Attruby's FDA Approval
2025: BridgeBio: Post Attruby Approval, Shares Don't Look Such Good Value - Rating Downgrade
2025: BridgeBio: Small Biotech Lining Up Dominos On Triple-Digit Sprint
2025: BridgeBio: Strong Start For Attruby
2025: Sales of BridgeBio’s new ATTR-CM heart drug blow past expectations
2025: The Play On BridgeBio Pharma: Great Expectations For Attruby

Jumps

*Key People: BridgeBio Pharma
Finance & Acquisitions: BridgeBio Pharma

Made with TheBrain